The American Gastroenterological Association has updated guidance for the treatment of ulcerative colitis to recommend using higher efficacy drugs in earlier stages of treatment, Medscape Medical News ...

An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a new trial shows. The treatment, tulisokibart, ...

DelveInsight's Ulcerative Colitis Market Insights report includes a comprehensive understanding of current treatment practices, ulcerative colitis emerging drugs, market share of individual therapies, ...

Credit: Getty Images What have we learned in recent years about the safety and efficacy of different biologics for the treatment of ulcerative colitis? Ulcerative colitis (UC) is a condition with a ...

Please provide your email address to receive an email when new articles are posted on . A greater proportion of patients in the PRA023 group achieved clinical remission at 12 weeks vs. placebo (26.5% ...

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...

A team led by clinicians and engineers has wrapped the plant-derived polyphenol pterostilbene (PSB) into prebiotic ...

Ulcerative colitis is a type of inflammatory bowel disease (IBD) that causes inflammation of the colon, and leads to symptoms such as fatigue, abdominal pain, and cramping. There is currently no cure ...

For the 907,000 Americans with ulcerative colitis, living with symptoms like urgent bowel movements, abdominal cramps, and loose or bloody stools can be overwhelming, but treatments can help keep ...

The ulcerative colitis market is experiencing steady growth driven by rising disease prevalence and increasing diagnosis rates worldwide. Expanding adoption of advanced biologics, small-molecule ...